180KShares reported
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
PFE · NYSE · Pharmaceuticals
Biopharmaceutical medicines and vaccines.
Last close, Oct 1, 2026
$28.12
Adjusted for splits and dividends
Last 12 months
+3.3%
S&P 500 +14.3% over the same dates
Market value
$160B
Last close × shares outstanding
Bets against the stock: 155M shares sold short (2.7% of shares outstanding), +2.4% vs the previous count, 4.9 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
3 insiders
$2.96M bought in total
Insiders selling, last 90 days
1 sale
$83K sold. Insiders sell for many reasons.
New federal contracts, 12 months
$652K
10 contracts, 83.2% from one agency
Revenue, fiscal 2025
$62.6B
-1.6% vs the year before
Net income, fiscal 2025
$7.77B
As reported in the annual filing
Shares outstanding
5.7B
As of Jul 29, 2026
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
9 different filers disclosed PFE within 90 days. Disclosed 521 days after the transaction; reported as an official range, not an exact amount.
Stock since the trade +6.9% · S&P 500 -1.1% · to Oct 1Traded 8 days after resultsStock 11% above its 52-week low and 8% below its high
391K → 429K shares held+10% of their stake
5 different filers disclosed PFE within 90 days. Disclosed 619 days after the transaction; reported as an official range, not an exact amount.
Stock since the trade +8.9% · S&P 500 -0.8% · to Oct 1Traded 1 day after resultsStock 9% above its 52-week low and 10% below its high
32K → 29K shares held−10% of their stake
No pre-arranged plan is mentioned in the filing
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
The boss of Pfizer spent $1M of their very own money to buy Pfizer shares. 2 other people at Pfizer bought some too, in the same month. Their pile of Pfizer shares grew by 10%.
Last 12 months, adjusted daily closes
Adjusted close went from $27.21 on Oct 1, 2025 to $28.12 on Oct 1, 2026 (+3.3%). Disclosed trades in the last 12 months: 3 insider purchases, 2 insider sales, 2 Congress purchases, 5 Congress sales. 1 group of purchases by several insiders within a few days.
8 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
2 notices filed with state agencies, covering 162 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
25 certified in FY2026 Q3, vs 38 a year earlier. 25 positions in total, median offered wage $132K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Short sale volume: 44.1% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 42.4%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 63K shares (about $1.82M) were not delivered on time for settlement on Sep 4, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.